Development of Respiratory Syncytial Virus Vaccine by Inducing Mucosal Immunity

RSV VACCINE COMPOSITION COMPRISING HEPATITIS B VIRUS-LIKE PARTICLES AS ADJUVANT

Trace

Technical Name	Influenza mucosal vaccine compositionpreparationapplication thereof
Project Operator	National Tsing Hua University
Project Host	吳夙欽
Summary	Provided is an influenza mucosal vaccine compositionpreparationapplication thereof. This composition contains an antigen fusion protein which includes an influenza virus antigena Type IIb heat-labile enterotoxin A subunit. Immunization with the antigen fusion protein induces cellularhumoral immune responses, including systemicmucosal immune responses, against a specific in
Technical Film
Scientific Breakthrough	Provided is an influenza mucosal vaccine compositionpreparationapplication thereof. This composition contains an antigen fusion protein which includes an influenza virus antigena Type IIb heat-labile enterotoxin A subunit. Immunization with the antigen fusion protein induces cellularhumoral immune responses, including systemicmucosal immune responses, against a specific in
Industrial Applicability	The market for seasonal influenza vaccines, sized at US$2.8 billion in 2008–2009 across the major markets, not including the potential of pandemic vaccines. The annual rate of influenza vaccine is approximately 12.6. Our invention provides a mucosal vaccine composition for both humanpoultry vaccine markets. Our invention has already been granted for the patents in USTaiwan.
Keyword	Vaccine mucosal intranasal immunization influenza virus hemagglutinin heat-labile enterotoxin A subunit fusion antigen adjuvant